Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.

Details

Language :

English

ISSN :

15257304

Volume :

19

Issue :

3

Database :

Complementary Index

Journal :

Clinical Lung Cancer

Publication Type :

Academic Journal

Accession number :

129329368

Full Text :

https://doi.org/10.1016/j.cllc.2017.12.011